KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Goodwill (2020 - 2025)

Historic Goodwill for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $47.8 million.

  • AbCellera Biologics' Goodwill changed 0.0% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $47.8 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, AbCellera Biologics' Goodwill stood at $47.8 million, which was down 0.0% from $47.8 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Goodwill peaked at $49.5 million during Q3 2021, and registered a low of $31.5 million during Q1 2021.
  • Moreover, its 5-year median value for Goodwill was $47.8 million (2021), whereas its average is $46.2 million.
  • Its Goodwill has fluctuated over the past 5 years, first skyrocketed by 5176.51% in 2021, then crashed by 333.83% in 2022.
  • AbCellera Biologics' Goodwill (Quarter) stood at $47.8 million in 2021, then changed by 0.0% to $47.8 million in 2022, then changed by 0.0% to $47.8 million in 2023, then changed by 0.0% to $47.8 million in 2024, then changed by 0.0% to $47.8 million in 2025.
  • Its Goodwill stands at $47.8 million for Q3 2025, versus $47.8 million for Q2 2025 and $47.8 million for Q1 2025.